Methods of screening for compounds which inhibit soluble .beta.-

Details Methods of screening for compounds which inhibit soluble .beta.- Methods of screening for compounds which inhibit soluble .beta.-

1993-06-17

1998-06-16

Allen, Marianne P.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

435 71, 435 72, 435 721, 435 41, 435 691, 435 792, 435 794, G01N 3353

Patent

active

057668469

ABSTRACT:
Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 5221607 (1993-06-01), Cordell et al.
patent: 5547841 (1996-08-01), Marotta et al.
Yankner et al, Science 245: 417-420, 28 Jul. 1989.
Bullock et al., "Techniques In Diagnostic Pathology", vol. 2, 1991, Academic Press (London), pp. 100-112.
Boller et al., "Biological Markers of Alzheimer's Disease", 1989, Springer-Verlag (Berlin), pp. 24-29.
Seubert et al., "Isolation and quantification of soluble Alzheimer's Beta-peptide from biological fluids", Nature Sep. 24, 1992, vol. 359, pp. 325-327.
Pennisi, "A Molecular Whodunit", Science News, vol. 145, No. 1, Jan. 1, 1994, pp. 8-11.
Haass et al., "Amyloid Beta-peptide is produced by cultured cells during normal metabolism", Nature, vol. 359, Sep. 24, 1992, pp. 322-325.
M.A. Winkler, "Tacrine for Alzheimer's Disease", JAMA, 271(13):1023-1024 (Apr. 6, 1994).
Seubert, P., et al. (1993) "Secretion of .beta.-Amyloid Precursor Protein Cleaved at the Amino Terminus of the .beta.-Amyloid Peptide" Nature 361:260-263.
Citron, M., et al. (1992) "Mutation of the .beta.-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases .beta.-Protein Production" Nature 360:672-674.
Alderson, J.P., et al. (1991) "Exact Cleavage Site of Alzheimer Amyloid Precursor in Neuronal PC-12 Cells" Neuroscience Letters 128:126-128.
Wisniewski et al. (1989) "Cerebrospinal Fluid-Based Laboratory Test for Alzheimer's Disease" Biological Markers of Alzheimer's Disease 1989, pp. 23-29.
Esch et al. "Cleavage of Amlyoid .beta. Peptide During Constitutive Processing of its Precursor", Science, 248:1122-1124 (1 Jun. 1990).
Palmert et al. "Soluble Derivatives of the .beta. Amyloid Protein Precursor of Alzheimer's Disease are Labeled by Antisera to the .beta. Amyloid Protein", Biochem. Biophys. Res. Commun., 165(1):182-188 (Nov. 30, 1989).
Haass et al. ".beta.-Amyloid Peptide and a 3-kDa Fragment are Derived by Distinct Cellular Mechanisms", J. Biol. Chem., 268(5):3021-3024 (Feb. 15, 1993).
Mullan et al. "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of .beta.-amyloid", Nature Genetics 1: 345-347 (Aug. 1992).
Glenner and Wong (1984) Biochem. Biophys. Res. Comm. 120:885.
Glenner and Wong (1984) Biochem. Biophys. Res. Comm. 122:1131.
Masters et al. (1985) Proc. Natl. Acad. Sci. USA 82:4245.
Selkoe et al. (1986) J. Neurochem. 46:1820.
Joachim et al. (1988) Brain Res. 474:100.
Hilbich et al. (1991) J. Mol. Biol. 218:149.
Barrow and Zagorski (1991) Science 253:179.
Burdick et al. (1992) J. Biol. Chem. 267:546.
Palmert et al. (1989) Proc. Natl. Acad. Sci. USA 86:6338.
Weidemann et al. (1989) Cell 57:115.
Henriksson et al. (1991) J. Neurochem. 56:1037.
Palmert et al. (1990) Neurology 40:1028.
Podlisny et al. (1990) Biochem. Biophys. Res. Comm. 167:1094.
Rumble et al. (1989) N. Engl. J. Med. 320:1446.
Schlossmacher et al. (1992) Neurobiol. Aging 13:421.
Wong et al. (1985)Proc. Natl. Acad. Sci. USA 92:8729.
Selkoe (1986) Nuerobiol Aging 7:425.
Pardridge et al. (1987) Biochem. Biophys. Res. Commun. 145:241.
Selkoe (1986) Nuerobiol. Aging 7:425.
Selkoe et al. (1989) Neurobiol. Aging 10:387.
Wisniewski in "Alzheimer's Disease", ed. Becker et al. p. 206.
Kim and Wisniewski in "Techniques in Diagnostic Pathology", ed. Bullock et al. Academic Press, Boston. pp. 106.
Wolozin et al. (1986) Science 232:648-650.
Ksiezak-Reder et al. (1988) J. Biol. Chem. 263:7943-7947.
Ueda et al. (1990) J. Nueroscience 10:3295-3304.
Lee et al. (1991) Science 251:675-678.

Affiliated with

Also associated with

Rating

Methods of screening for compounds which inhibit soluble .beta.- does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of screening for compounds which inhibit soluble .beta.-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for compounds which inhibit soluble .beta.- will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1723965